Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab
A
A
Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107.
McCrea
J B
JB
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D014487:Centers for Medicare and Medicaid Services, U.S.; D004334:Drug Administration Schedule; D016527:Drug Costs; D004921:Erythropoietin / Q000008:administration & dosage / Q000191:economics* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006436:Hemodialysis Units, Hospital / Q000191:economics*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000191:economics; D006278:Medicare / Q000191:economics*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D012051:Reimbursement Mechanisms; D006435:Renal Dialysis / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins; D004921:Erythropoietin